We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DENTSPLY SIRONA Inc. (XRAY - Free Report) recently announced preliminary results for fourth-quarter 2018 wherein the top line surpassed the Zacks Consensus Estimate of $1.02 billion.
Revenues totaled at $1.06 billion, showing a fall of 2.9% year over year.
Adjusted earnings per share came in at 58 cents, beating the Zacks Consensus Estimate of 54 cents. Earnings declined 29.3% year over year.
Investors Cheerful
DENTSPLY’s preliminary fourth-quarter 2018 results seem to impress investors. Share price of this Zacks Rank #3 (Hold) stock rose 4.6% to close at $49.13 since the release.
In the past year, shares of DENTSPLY have declined 12.1%, comparing favorably with the industry's 1.3% fall. The current level is also lower than the S&P 500’s rally of 3.3%.
DENTSPLY SIRONA Inc. Price, Consensus and EPS Surprise
Revenues in 2018 are expected at $4 billion, surpassing the Zacks Consensus Estimate of $3.94 billion. Revenues fell 0.2% from 2017.
Earnings per share for 2018 were $2.01, beating the Zacks Consensus Estimate of $1.97. The figure dropped 24.4% from 2017.
Quarter Highlights
Revenues in the fourth quarter are expected to see solid year-over-year increase of 4.6% in Europe and 1.4% in rest of the world. However, U.S. revenues declined 14.7% on a year-over-year basis in the quarter.
Fourth-quarter Consumable revenues increased 3.4% year over year. Notably, the segment benefited from a recovery in shipment levels at the company’s European distribution center in Venlo, the Netherlands.
Technology & Equipment revenues declined 7.4% year over year.
2019 View
For 2019, DENTSPLY expects adjusted earnings per share within the range of $2.25-$2.40. The mid-point of $2.32 of the guided range lies above the Zacks Consensus Estimate of $2.15.
However, portfolio initiatives are expected to negatively impact 2019 revenues.
Key Picks
Some better-ranked stocks in the broader medical space are Abbott Laboratories (ABT - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) and Surmodics, Inc. (SRDX - Free Report) .
Abbott’s long-term earnings growth rate is projected at 11.7%. The stock has a Zacks Rank #2 (Buy).
Merit Medical’s long-term earnings growth rate is projected at 13%. The stock has a Zacks Rank #2.
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
Image: Bigstock
DENTSPLY's (XRAY) Preliminary Q4 Results Cheer Investors
DENTSPLY SIRONA Inc. (XRAY - Free Report) recently announced preliminary results for fourth-quarter 2018 wherein the top line surpassed the Zacks Consensus Estimate of $1.02 billion.
Revenues totaled at $1.06 billion, showing a fall of 2.9% year over year.
Adjusted earnings per share came in at 58 cents, beating the Zacks Consensus Estimate of 54 cents. Earnings declined 29.3% year over year.
Investors Cheerful
DENTSPLY’s preliminary fourth-quarter 2018 results seem to impress investors. Share price of this Zacks Rank #3 (Hold) stock rose 4.6% to close at $49.13 since the release.
In the past year, shares of DENTSPLY have declined 12.1%, comparing favorably with the industry's 1.3% fall. The current level is also lower than the S&P 500’s rally of 3.3%.
DENTSPLY SIRONA Inc. Price, Consensus and EPS Surprise
DENTSPLY SIRONA Inc. Price, Consensus and EPS Surprise | DENTSPLY SIRONA Inc. Quote
2018 Results
Revenues in 2018 are expected at $4 billion, surpassing the Zacks Consensus Estimate of $3.94 billion. Revenues fell 0.2% from 2017.
Earnings per share for 2018 were $2.01, beating the Zacks Consensus Estimate of $1.97. The figure dropped 24.4% from 2017.
Quarter Highlights
Revenues in the fourth quarter are expected to see solid year-over-year increase of 4.6% in Europe and 1.4% in rest of the world. However, U.S. revenues declined 14.7% on a year-over-year basis in the quarter.
Fourth-quarter Consumable revenues increased 3.4% year over year. Notably, the segment benefited from a recovery in shipment levels at the company’s European distribution center in Venlo, the Netherlands.
Technology & Equipment revenues declined 7.4% year over year.
2019 View
For 2019, DENTSPLY expects adjusted earnings per share within the range of $2.25-$2.40. The mid-point of $2.32 of the guided range lies above the Zacks Consensus Estimate of $2.15.
However, portfolio initiatives are expected to negatively impact 2019 revenues.
Key Picks
Some better-ranked stocks in the broader medical space are Abbott Laboratories (ABT - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) and Surmodics, Inc. (SRDX - Free Report) .
Abbott’s long-term earnings growth rate is projected at 11.7%. The stock has a Zacks Rank #2 (Buy).
Merit Medical’s long-term earnings growth rate is projected at 13%. The stock has a Zacks Rank #2.
Surmodics’ long-term earnings growth rate is expected at 10%. The stock flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>